ViiV Healthcare's new data shows promising maternal and pregnancy outcomes for Apretude use

Retrieved on: 2024-07-23 17:32:24

Tags for this article:

Click the tags to see associated articles and topics

ViiV Healthcare's new data shows promising maternal and pregnancy outcomes for Apretude use. View article details on hiswai:

Excerpt

ViiV Healthcare has released new data demonstrating the safety and efficacy of Apretude (cabotegravir long-acting for PrEP) during pregnancy.

Article found on: www.outsourcing-pharma.com